Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Biomat USA
AddedFeb 13, 2024
UpdatedJun 18, 2026
Biomat USA

Biomat USA

Public

Grifols, established in 1950, operates over 175 plasma donation centers across the US, collecting protein-rich plasma for life-saving therapies.

HQ
Los Angeles, CA, US
Founded
1986
Overview
Compare
Fundraising
Employees
Website

Biomat USA, a subsidiary of Grifols, was established to focus on the collection of protein-rich plasma from donors. The core mission is to save lives by providing essential plasma for therapies that treat patients with immune deficiencies, hemophilia, and other genetic conditions. With over 175 plasma donation centers across the United States, Biomat USA offers a convenient and crucial service to both donors and patients in need of plasma-derived treatments.

Notable affiliated individuals include the leadership team at Grifols, which has a long history in the healthcare sector since its founding in 1950. Key achievements for Biomat USA include expanding its network of donation centers and contributing significantly to the availability of life-saving plasma therapies. The overall impact of Biomat USA is profound, as it plays a critical role in the healthcare system by ensuring a steady supply of plasma for medical treatments, thereby improving and saving countless lives.

Biomat USA - Similar Companies

Grifols logo

Grifols

grifols.com

Haemonetics logo

Haemonetics

haemonetics.com

B Positive Plasma logo

B Positive Plasma

bpositivetoday.com

BioLife Solutions logo

BioLife Solutions

Athersys logo

Athersys

Stemcyte logo

Stemcyte

stemcyte.com

Velico Medical logo

Velico Medical

veli.co

Secure Transfusion Services logo

Secure Transfusion Services

Biomat Sciences logo

Biomat Sciences

Humabiologics logo

Humabiologics

humabiologics.com

Circle Biologics logo

Circle Biologics

FloBio logo

FloBio

flobiollc.com

Celularity logo

Celularity

celularity.com

Becton Dickinson logo

Becton Dickinson

MacroGenics logo

MacroGenics

macrogenics.com

Biomat USA - Quick Facts

Who are Biomat USA's competitors?

Companies similar to Biomat USA include Grifols, Haemonetics, B Positive Plasma and BioLife Solutions.

When was Biomat USA founded?

Biomat USA was founded in 1986.

Where is Biomat USA's headquarters located?

Biomat USA's headquarters is located in Los Angeles, CA, US.

When was Biomat USA's last funding round?

Biomat USA's most recent funding round was for $1B (USD) in June 2021.

How much has Biomat USA raised to-date?

As of Jun 30, 2021, Biomat USA has raised a total of $1B (USD).

How many employees does Biomat USA have?

Biomat USA has 328 employees as of Feb 4, 2024.

Biomat USA - Classification

Industry
  • Retail
Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Transactional
Customer
  • Consumers
Main Product
  • Plasma Collection
Tags
  • Distribution
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 621000Ambulatory Health Care Services
  • 621400Outpatient Care Centers
  • 621490Other Outpatient Care Centers
  • 621491HMO Medical Centers
SIC
  • 8010Offices And Clinics Of Doctors Of Medicine
  • 8011Offices And Clinics Of Doctors Of Medicine